Literature DB >> 2401790

Comparative long-term effects in a mouse model system of influenza whole virus and purified neuraminidase vaccines followed by sequential infections.

B E Johansson1, E D Kilbourne.   

Abstract

A comparison of inactivated whole influenza virus vaccine and purified influenza neuraminidase (NA) in BALB/c mice repeatedly challenged by homologous or heterologous H3N2 variant infections demonstrated an initial superiority of whole virus vaccine but the ultimate superiority of NA vaccine in immunization after one or two boosting infections. Parenteral administration of either vaccine followed by infection was much more effective than infection alone in the induction of either homologous or heterologous immunity. On the basis of this model simulation of human experience and other earlier studies, it seems that purified NA vaccine may offer an important new strategy as an initial step in immunization against influenza in humans.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2401790     DOI: 10.1093/infdis/162.4.800

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  5 in total

1.  Immunization with purified N1 and N2 influenza virus neuraminidases demonstrates cross-reactivity without antigenic competition.

Authors:  B E Johansson; E D Kilbourne
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

Review 2.  Influenza Neuraminidase: A Neglected Protein and Its Potential for a Better Influenza Vaccine.

Authors:  Luca T Giurgea; David M Morens; Jeffery K Taubenberger; Matthew J Memoli
Journal:  Vaccines (Basel)       Date:  2020-07-23

3.  Cooperativity between CD8+ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity.

Authors:  Brian J Laidlaw; Vilma Decman; Mohammed-Alkhatim A Ali; Michael C Abt; Amaya I Wolf; Laurel A Monticelli; Krystyna Mozdzanowska; Jill M Angelosanto; David Artis; Jan Erikson; E John Wherry
Journal:  PLoS Pathog       Date:  2013-03-14       Impact factor: 6.823

4.  Long-Lasting Cross-Protection Against Influenza A by Neuraminidase and M2e-based immunization strategies.

Authors:  Michael Schotsaert; Tine Ysenbaert; Anouk Smet; Bert Schepens; Dieter Vanderschaeghe; Svetlana Stegalkina; Thorsten U Vogel; Nico Callewaert; Walter Fiers; Xavier Saelens
Journal:  Sci Rep       Date:  2016-04-13       Impact factor: 4.379

5.  Contribution of Neuraminidase to the Efficacy of Seasonal Split Influenza Vaccines in the Ferret Model.

Authors:  Miruna E Rosu; Adinda Kok; Theo M Bestebroer; Dennis de Meulder; Elwin P Verveer; Mark R Pronk; Lennard J M Dekker; Theo M Luider; Mathilde Richard; Judith M A van den Brand; Ron A M Fouchier; Sander Herfst
Journal:  J Virol       Date:  2022-02-02       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.